Cerus (CERS) Stock Analysis & AI Equity Report
Cerus (CERS) overview
Cerus (CERS) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 234m and operating profit of USD -8.7m; the year-end share price was 2.06 USD and market capitalisation was USD 396m. Cerus is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Cerus's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Cerus
Cerus develops and commercializes the INTERCEPT Blood System to reduce blood-borne pathogens in donated blood components intended for transfusion. The system is used with platelets and plasma, and to produce fibrinogen complex and pathogen-reduced plasma. Cerus sells platelet and plasma systems through direct sales and distributors, and offers fibrinogen complex or production kits in the United States. Its red blood cell system remains in development.
Generate the Cerus report
Cerus is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Cerus and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Cerus
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.